Oncology | Drugs in Discovery | UNITED STATES

HiFiBiO Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Kite and Hifibio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia

Lead Product(s): Anti-AML specific antibodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Kite Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 03, 2020

Details:

Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite’s use in cell therapies.

Harbour BioMed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Harbour BioMed Collaborates with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases

Lead Product(s): Antibodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Vir Biotechnology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 24, 2020

Details:

HBM will leverage its tools in next-generation technologies including its transgenic Harbour Mice® platforms to generate antibodies for the collaboration.

Tango Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: $6,295.0 million Upfront Cash: $125.0 million

Deal Type: Collaboration August 17, 2020

Details:

Under the expanded multi-year collaboration, Tango will continue to leverage its proprietary, CRISPR-enabled functional genomics target discovery platform to identify novel immune evasion targets. The number of targets covered will expand from five to 15.

Twist Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Seismic Bio Partners With Twist Bioscience for Discovery and Optimization of Antibodies

Lead Product(s): Bispecific antibodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Seismic Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership August 04, 2020

Details:

Twist Biopharma will use Hyperimmune Libraries, two fully human antibody libraries focused on the heavy chain complementary determining region 3 (CDR3) loop diversity involved in antigen recognition, to identify antibodies that bind to the specified immuno-oncology targets.

PMV Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

PMV Pharma Raises $70M for Tumor Suppressor Programs

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Avoro Capital

Deal Size: $70.0 million Upfront Cash: Undisclosed

Deal Type: Series D Financing August 03, 2020

Details:

The proceeds from the financing provides PMV Pharma with the resources to expand its pipeline and to potentially advance multiple p53 therapies into the clinic.

Schrodinger

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Schrödinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Viva Biotech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 28, 2020

Details:

Under the terms of the collaboration, Schrödinger will identify drug discovery targets for which there are currently no crystal structures in the public domain, including those that could lead to first-in-class therapeutic candidates for its internal pipeline.

Revitope Oncology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Junshi Taps Revitope for Next-Gen Anticancer Bispecifics

Lead Product(s): Immunotherapy compound

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Shanghai Junshi Biosciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 14, 2020

Details:

Revitope will leverage its proprietary protein engineering platform together with Junshi's novel antibody components to develop dual-antigen targeting cancer therapies. Revitope is granting Junshi an exclusive license on products arising from the research collaboration.

Foghorn Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Merck Dangles up to $425 million to Team with Flagship’s Foghorn Therapeutics on Drugging the Shape of DNA

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: $425.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration July 08, 2020

Details:

Under the collaboration agreement, Foghorn will grant Merck exclusive global rights to develop and commercialize drugs that target dysregulation of a single transcription factor.

Atreca

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

Lead Product(s): T Cell Engaging Bispecific Antibodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Xencor

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 08, 2020

Details:

Under the terms of the agreement, the companies will engage in a three-year discovery program. Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.

Twist Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Takeda Teams up with Twist Bioscience to Boost Biologics R&D

Lead Product(s): Antibodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Takeda Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 08, 2020

Details:

Under the pact Takeda will tap the Twist Bioscience's phage display libraries for the discovery, validation and optimization of antibodies in Takeda’s pipeline of biologics across its four core areas: oncology, rare diseases, neuroscience and gastroenterology.

Find

Find Novel Oncology Drugs in Discovery in UNITED STATES

United States

Product Type

Companies

HiFiBiO Therapeutics

Kite and Hifibio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia

Harbour BioMed

Harbour BioMed Collaborates with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases

Tango Therapeutics

Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

Twist Bioscience

Seismic Bio Partners With Twist Bioscience for Discovery and Optimization of Antibodies

PMV Pharma

PMV Pharma Raises $70M for Tumor Suppressor Programs

Schrodinger

Schrödinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets

Revitope Oncology

Junshi Taps Revitope for Next-Gen Anticancer Bispecifics

Foghorn Therapeutics

Merck Dangles up to $425 million to Team with Flagship’s Foghorn Therapeutics on Drugging the Shape of DNA

Atreca

Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

Twist Bioscience

Takeda Teams up with Twist Bioscience to Boost Biologics R&D